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1. Introduction
DNA repair mechanisms are crucial for the maintenance of genome’s integrity. When DNA
damage is not repaired promptly, that may pose a serious threat to genomic stability and can
contribute to carcinogenesis. On the other hand, the core molecular mechanism of action in
several cancer treatments including chemotherapeutic agents and radiation therapy is
induction of DNA damage and the efficacy of DNA repair mechanisms may influence the
outcome of cancer treatment. Genetic variability of DNA repair proteins can modify the ability
to repair DNA damage and may therefore play an important role in both cancer susceptibility
and the outcome of cancer treatment.
DNA damage arises from exposure to endogenous or exogenous factors, including chemo‐
therapeutic agents and radiation therapy [1]. There are several forms of DNA damage and
therefore several mechanisms involved in their repair. Complex changes such as double strand
breaks (DSBs) can lead to chromosome loss, chromosomal rearrangements or apoptosis and
as a result can have a significant impact on cellular processes. DSBs represent one of the most
detrimental forms of DNA damage because both strands of DNA are damaged and are thus
especially challenging for efficient and accurate DNA repair [2]. One of the important path‐
ways involved in DSB repair is HRR, a complex mechanism consisting of several steps that
requires coordinated interplay of various enzymes [3]. This chapter focuses on homologous
recombination repair (HRR) and summarizes the current knowledge on how genetic variabil‐
ity in this pathway influences cancer susceptibility and treatment outcome.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. Homologous recombination repair pathway
HRR is crucial for the repair of DSBs, but is also involved in repair of other types of DNA
damage, such as interstrand crosslinks. HRR ensures complete repair of DSBs because the
undamaged homologous chromosome serves as a template to repair the damage.
In the first step of HRR, MRN complex is essential for recognition of DSBs. MRN complex
consists of three proteins: meiotic recombination 11 homologue (MRE11), DNA repair protein
RAD50 (RAD50) and nibrin (NBN). MRN recruits different enzymes to the site of DNA damage
and activates them [4]. In the beginning, the broken ends of DSBs are processed to single
stranded 3’ ends. DNA repair protein RAD51 homolog 1 (RAD51) then binds to DNA and
forms a nucleoprotein filament. With the help of mediator proteins such as X-ray repair cross-
complementing group 3 (XRCC3) and XRCC2, RAD51 catalyses the central reaction of HRR:
the search for a homologous template and strand transfer between the damaged region and
the undamaged homologous chromatid. The 3’ end of the damaged strand invades the
homologous chromatid and is elongated by DNA polymerase using the complementary strand
of the homologous chromatid as a template, resulting in the formation of Holliday junctions.
After resynthesis and ligation of the damaged region, resolvase is needed for the resolution of
Holliday junctions. Resolution can lead to either crossover or non-crossover products, but it
always results in two intact double-stranded DNA molecules [5].
3. Genetic variability in homologous recombination repair genes
DNA repair mechanisms can be less effective in some individuals, leading to increased cancer
susceptibility. Rare mutations in DNA repair genes that result in decreased DNA repair
capacity have been linked to different hereditary cancers. DNA repair capacity may also be
influenced by genetic polymorphisms that were identified in these genes. In particular,
common functional single nucleotide polymorphisms (SNPs) leading to amino acid substitu‐
tions as well as SNPs in promoter or miRNA binding sites may influence the activity, stability
or expression of DNA repair proteins.
The majority of cancer susceptibility and pharmacogenetic studies related to HRR has focused
on genetic variability of NBN, RAD51, XRCC2, and XRCC3. Most commonly investigated SNPs
in these genes, their predicted function and their minor allele frequencies (MAFs) in population
of European descent are presented in Table 1.
3.2. NBN
MRN complex is involved in DSB recognition in different repair pathways, not only in HRR
[14], suggesting that NBN may play a crucial part in DNA repair. NBN consists of three
functional regions [6]. The N-terminal region binds to phosphorylated histone H2AX (γ-H2AX)
and allows the MRN complex to move close to the sites of DSBs [6]. The central region is
involved in signal transduction for damage response, while the C-terminal region is involved
in MRE11 binding.
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Gene rs number Polymorphism Location Predicted function MAFa
NBN rs1805794 p.Glu185Gln Exon, nonsynonymous Affects interaction withBRCA1 [6] 0.304
rs709816 p.Asp399Asp Exon, synonymous Affects splicing [7] 0.357
rs1063054 c.*1209A>C 3’ UTR Affects miRNA binding [8] 0.317
rs2735383 c.*541G>C 3’ UTR Affects miRNA binding[8-10] 0.312
RAD51 rs1801320 c.-98G>C 5’ UTR Enhances promoter activity[11] 0.067
rs1801321 c.-61G>T 5’ UTR Enhances promoter activity[11] 0.467
XRCC3 rs1799794 c.-316A>G 5’ UTR Affects transcription factorbinding [8] 0.184
rs861539 p.Thr241Met Exon, nonsynonymous Might affect proteinstructure or function [12] 0.433
XRCC2 rs3218536 p.Arg188His Exon, nonsynonymous Modified sensitivity to DNAdamaging agents [13] 0.094
aMAF: minor allele frequency in population of European descent included in HapMap project (HapMap-CEU)
Table 1. Most commonly investigated HRR SNPs and their predicted function.
Mutations in the NBN gene may lead to autosomal recessive disorder Nijmegen breakage
syndrome, presenting with immunodeficiency, increased cancer risk and radiation sensitivity
[6]. Rare NBN mutations were associated with chromosomal instability and increased sus‐
ceptibility to cancer [15] and are presented in Table 2. The most common is a deletion of five
nucleotides (675del5), common in Slavic populations [16], that leads to protein truncation [17].
Mutation rs number Predicted function
Asp95Asn rs61753720 May affect protein-protein interactions [18], not highly damaging [19]
Ile171Val rs61754966 Affects protein structure and protein-protein interactions [20]
Arg215Trp rs61753718 Impairs histone γ-H2AX binding [4]
Pro266Leu rs769420 Probably damaging effect [8]
657del5 Leads to protein truncation [17]
Table 2. Most common mutations in the NBN gene.
Besides rare mutations, several common SNPs have been described in both the coding region
and the regulatory regions of NBN gene (Table 1). By far the most frequently investigated
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polymorphism is NBN rs1805794 (p.Glu185Gln) that leads to amino acid change in BRCA1 C-
terminal domain [6] and could therefore affect protein-protein interactions with other HRR
proteins. Polymorphic rs1805794 C allele was previously associated with decreased DNA
damage detected with comet assay in healthy individuals [21]. It was also shown to modify
the frequencies of chromatid-type aberrations [22]. NBN rs709816 (p.Asp399Asp) is a synon‐
ymous SNP that does not change the amino acid sequence in the central region of NBN. Two
other NBN SNPs that may be functionally important, rs2735383 (c.*541G>C) and rs1063054
(c.*1209A>C), are located in the 3’ untranslated region (UTR). Rs1063054 was predicted to affect
miRNA binding, but that was not yet validated [4, 8]. On the other hand, studies have already
shown that rs2735383 modifies miR-629 and miR-509-5p binding and the polymorphic C allele
was associated with lower transcriptional activity [9, 10].
3.2. RAD51
RAD51 is a key enzyme of HRR that has both DNA binding and ATPase activities. It interacts
with many proteins, for example RAD51 paralogs, BRCA1, BRCA2 and RAD54 [23]. Several
SNPs have been described in RAD51 gene, but only few are located in the coding region. On
the other hand, there are SNPs in the 5’ UTR that may affect both gene transcription and protein
expression, such as RAD51 rs1801320 (c.-98G>C) and rs1801321 (c.-61G>T) that were reported
to increase promoter activity [11, 24]. RAD51 rs1801320 polymorphism was also associated
with protein over-expression and increased DNA repair [11]. The polymorphic rs1801321 allele
facilitates binding of a transcription factor, thus increasing the transcription of the RAD51 gene
[24]. This polymorphism was associated with decreased DNA damage detected with comet
assay in healthy individuals [21] and lower amount of gamma radiation-induced chromatid
breaks [24], suggesting a protective effect.
3.3. XRCC3
XRCC3 is one of XRCC proteins involved in the protection of cell from ionizing radiation and
belongs to the RAD51 family [25]. XRCC3 deficiency affects RAD51 foci formation and leads
to increased genetic instability and sensitivity to DNA damaging agents [26].
Only a few putatively functional SNPs have been described in the XRCC3 gene. Among them,
non-synonymous polymorphism rs861539 (p.Thr241Met) and rs1799794 (c.-316A>G) poly‐
morphism in 5’ UTR were the most frequently studied. XRCC3 rs861539 changes the amino
acid residue, which could affect protein structure or function [12]. Polymorphic rs861539 allele
was previously associated with decreased DNA damage detected with comet assay in healthy
individuals [21] and had a protective effect against chromosomal aberrations [27], but not in
all studies [28].
3.4. XRCC2
XRCC2 is also one of the RAD51 paralogs, necessary for successful HRR. It is essential in the
early stages of HRR for the formation of RAD51 foci, but it does not require ATP binding [29].
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Studies have shown that XRCC2 deficiency leads to defects in RAD51 foci formation, markedly
decreased HRR and increased DNA damage, as well as hypersensitivity to radiation [29-31].
Among SNPs that have been described in XRCC2, the only non-synonymous rs3218536
(p.Arg188His) polymorphism attracted the most attention, despite its relatively low MAF and
very few individuals carrying two polymorphic alleles. A deletion or a non-conservative
substitution in the position 188 markedly increased sensitivity to mitomycin C induced DNA
damage, but the common Arg188His substitution only had a small influence on damage
sensitivity [32]. As the variant XRCC2 188His allele was associated with increased resistance
to cisplatin induced DNA damage, it was suggested that it could be associated with increased
DNA repair capacity [13]. The observed differences could be partly due to the use of different
DNA damaging agents. It was suggested that lesions caused by different agents could require
more precise regulation of protein expression to reach full repair potential [13].
4. Genetic variability in HRR and cancer susceptibility
Due to important role of DSBs in carcinogenesis, several studies have investigated the role of
HRR SNPs in cancer susceptibility. To overcome the problem of non-concordant effects
observed in some studies, several meta-analyses have been performed. Meta-analyses have
the advantage of larger sample sizes and better statistical power. Their results suggested that
HRR SNPs may contribute to cancer susceptibility, but their role may not be the same in all
cancer types or in all populations, especially as MAFs can differ substantially for some
polymorphisms. Another shortcoming of the meta analyses is that gene-gene and gene-
environmental interactions could modify the role of SNPs, but the results of meta-analyses are
usually not adjusted for confounders. In addition, it is difficult to perform meta-analyses in
rare cancers.
4.1. NBN
Genetic variability in NBN was associated with susceptibility to different hematological and
solid tumors. Several meta-analyses have been published to date, showing that NBN mutations
and polymorphisms may have different effects in different cancer types (Table 3).
Mutation / SNP Reference N of studies N of cases/controls Cancer type Major observation*
Ile171Val
Bogdanova, 2008 [33] 4 2954/2531 Breast No association
Gao, 2013 [4]
10 4516/9951 Overall Increased risk
5 3301/3904 Breast No association
2 182/720 Lymphoma Increased risk
Zhang, 2012 [34] 5 3273/4004 Breast No association
Arg215Trp Gao, 2013 [4] 9 6728/9508 Overall Increased risk
657del5 Zhang, 2012 [34] 9 7534/14034 Breast Increased risk
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Mutation / SNP Reference N of studies N of cases/controls Cancer type Major observation*
Zhang, 2013 [35] 10 25365 Breast Increased risk
Gao, 2013 [4]
21 15184/54081 Overall Increased risk
10 9091/15154 Breast Increased risk
5 1053/9524 Lymphoma Increased risk
2 3440/2490 Prostate Increased risk
rs1805794
Vineis, 2009 [36] 4 ∑4825 Bladder Increased risk
Lu, 2009 [37]
17 9734/10325 Overall Borderline increasedrisk
6 4595/3603 Breast No association
3 605/639 Lung No association
3 1446/1452 Bladder No association
Stern, 2009 [38] 13 6348/6752 Bladder Modestly increased risk
Wang, 2010 [39] 10 4452/5665 Breast
Decreased risk
Not credible, some
mistakes [40]
Wang, 2013 [41] 6 2348/2401 Lung Increased risk
Yao, 2013
[42] 14 6642/7138 Breast No association
He, 2014 [43]
48 17159/22002 Overall No association
7 2837/2973 Urinary system Increased risk
5 1682/2213 Digestive system Decreased risk
Zhang, 2014 [44] 8 3542/4210 Urinary systemcancer
Increased risk, especially
in bladder cancer
Gao, 2013 [4] 42 18901/21430
No association in
subgroup analysis by
cancer type,
heterogeneity too big for
overall analysis
rs2735383 Gao, 2013 [4] 13 7561/8432 Overall Increased risk4 2915/3035 Lung Increased risk
rs1063054 Gao, 2013 [4] 9 2757/5796 Overall Increased risk
*the direction of association for the mutated or polymorphic allele; ∑ - the total number of cases and controls
Table 3. Observed influence of NBN genetic variability on cancer risk in meta-analyses.
Rare mutations in the NBN gene have a more deleterious effect on the gene function and
therefore have a bigger influence on cancer risk [4]. Even though the results of individual
studies differed, several meta-analyses observed similar influence of various NBN mutations
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on cancer risk (Table 3). NBN 657del5 mutation was associated with increased overall cancer
risk, as well as increased risk for breast cancer, prostate cancer, and lymphoma [4, 34, 35].
Interestingly, Ile171Val mutation did not predispose to increased breast cancer risk [4, 33, 34],
but it was associated with overall increased risk of cancer and increased lymphoma risk [4].
The results of the meta-analysis showed that Arg215Trp mutation also significantly increased
the overall cancer risk, in contrast with Asp95Asn and Pro266Leu mutations that were not
associated with increased cancer risk [4].
Most of the meta-analyses investigating the role of NBN polymorphisms in cancer suscepti‐
bility were limited to the non-synonymous rs1805794 SNP (Table 3). Most studies have
confirmed that polymorphic allele modestly increases bladder cancer risk [36, 38, 43]. The
results in other cancer types were more ambiguous as some studies observed an association
with increased cancer risk, but several did not (Table 3). Interestingly, in one meta-analysis
decreased risk was observed for cancers of digestive system [43]. Decreased risk was also
reported in some studies in rare cancer types such as acute myeloid leukemia [45] or osteo‐
sarcoma [46]. The observed discrepancies could be due to large heterogeneity between studies.
Also NBN genotype distribution differs among populations, as the variant rs1805794 C allele
is more common in some populations [21, 47]. Therefore it is not surprising that meta-analyses
observed significant influence of NBN SNPs only in specific subgroups: only in Caucasians
[37], only in Asians [41], or only among smokers [38]. Further studies should pay special
attention to these differences as they could help explain discrepancies among studies. As the
effect of a particular SNP may differ among cancer types, analyses should be stratified by
cancer type. However, this can present a problem in rare cancer types, as it may be difficult to
achieve sufficient power.
Among other NBN SNPs, one meta-analysis included two SNPs in the 3’ UTR, rs2735383 and
rs1063054. The results suggested that both SNPs contribute to increased overall cancer risk [4].
However, when the analysis was stratified by cancer type, rs2735383 was only associated with
increased lung cancer risk, but no significant association with bladder, nasopharyngeal cancer
or leukemia was observed. NBN rs709816 was not associated with modified cancer risk in any
of the studies [17].
4.2. RAD51
RAD51 rs1801320 is the most studied polymorphism in this gene despite its relatively low
MAF. Several meta-analyses were published on the influence of rs1801320 on breast cancer
risk until 2011, but they were mostly inconclusive [48-52]. Several shortcomings in the analyses
associated with data and inclusion of these studies were later noted [53], suggesting that many
of these studies were unreliable. More recent meta-analyses are presented in Table 4. Some
suggested that rs1801320 may increase breast cancer susceptibility [54, 55], but one of the
studies suggested a potential role of this polymorphism only in individuals with BRCA2
mutations [56]. BRCA2 directly interacts with RAD51 and influences intracellular transport as
well as function of RAD51 [57], thus playing an important role in HRR, so these observations
are biologically plausible.
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RAD51 rs1801320 SNP was also associated with increased overall cancer risk in the two largest
meta-analyses that included more than 40 individual studies [54, 55], however no association
was observed in an earlier study [56]. Increased risk for several cancer types, including
hematological malignancies, ovarian, colorectal, and endometrial cancer was observed in a
recent study [55], but not all were replicated in other studies (Table 4).
Another RAD51 polymorphism, rs1801321 was investigated in only one meta-analysis and
even though overall cancer risk was not modified [54], the decreased risk in carriers of
polymorphic allele for head and neck cancer confirmed the results of previous studies [24].
Decreased breast cancer risk was also observed in carriers of polymorphic allele [58]. The
suggested protective role of rs1801321 is in concordance with the described biological effect
of this polymorphism.
Reference N of studies N of cases/controls Cancer type Major observation*
He, 2014 [59] 10 2656/3725
Myelodysplastic syndrome and
acute leukemia No association
3 726/604 Myelodysplastic syndrome Increased risk
Wang, 2013 [56]
39 19068/22630 Overall No association
7 1605/3121 Acute myeloid leukemia No association
14 11709/11291 Breast No association
6 2388/4411 Ovarian No association
Cheng, 2014 [60]
22 6836/8507 Overall No association
4 1237/1340 Squamous cell carcinoma of thehead and neck Increased risk
4 753/720 Colorectal No association
5 2001/2420 Ovarian No association
9 2845/4027 Acute leukemia No association
Zhao, 2014 [54] 42 19142/20363 Overall Increased risk17 11716/9839 Breast Increased risk
Shi, 2014 [61] 10 2648/4369 Ovarian No association
Li, 2014 [62] 6 1764/3469 Acute myeloid leukemia No association
Zhang, 2014 [55]
45 28956/28372 Overall Increased risk
19 19171/17198 Breast Increased risk
7 2169/3629 Hematological malignancies Increased risk
4 3598/3002 Ovarian Increased risk
4 1202/1216 Head and neck No association
*the direction of association for the polymorphic allele
Table 4. Observed influence of RAD51 rs1801320 on cancer risk in meta-analyses.
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4.3. XRCC3
XRCC3 is by far the most studied HRR gene in cancer susceptibility studies. More than 50
meta-analyses focusing on XRCC3 rs861539 SNP have been published, so only recent studies
published in 2014 are presented in Table 5. The polymorphic rs861539 allele was associated
mostly with increased breast and bladder cancer risk, but decreased lung or skin cancer risk
[63-65]. An interesting observation is almost consistently observed increased cancer risk in
carriers of polymorphic allele from Asian populations, while usually no association was
observed in Caucasian populations or when different populations were combined.
Reference N of studies N of cases/controls Cancer type Major observation*
Mao, 2014 [66] 36 23812/25349 Breast Slightly increased risk,especially in Asians
Xing, 2014 [67] 8 3215/3106 Lung No association
Yuan, 2014 [12] 4 5173/7800 Ovarian No association
Feng, 2014 [68] 8 3455/4435 Glioma No association
Li, 2014 [69] 5 1507/3623 Larynx No association
Adel Fahmideh,
2014 [70] 5 3374/3734 Glioma No association
Chen, 2014 [26] 15 4329/7291 Overall No association
8 2056/3920 Non-melanoma skin cancer Decreased risk
5 1324/2209 Basal cell carcinoma Decreased risk
3 732/1711 Squamous cell carcinoma Decreased risk
Qin, 2014 [71] 9 2209/3269 Gastric No overall, association,increased risk in Asians
Yu, 2014 [72] 6 723/1399 Thyroid
No overall association,
increased risk in
Caucasians
Yan, 2014 [73] 7 1070/1850 Leukemia No overall association,increased risk in Asians
Yan, 2014 [74] 7 3635/5473 Ovarian No association
Qin, 2014 [75] 15 2339/4162 Leukemia
No overall association,
increased risk in acute
myeloid leukemia
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Reference N of studies N of cases/controls Cancer type Major observation*
Wang, 2014 [76] 12 2209/3269 Gastric No overall association,decreased risk in Asians
Du, 2014 [77] 23 7777/9868 Overall (Chinese mainlandpopulation)
Increased risk, especially
cervical and
nasopharyngeal cancer
Wang, 2014 [78] 10 4136/5233 Glioma No overall association,increased risk in Asians
Liu, 2014 [79] 13 4984/7472 Brain tumors No overall association,increased risk in Asians
Ma, 2014 [80] 18 5667/7609 Bladder Increased risk
Peng, 2014 [81] 16 5608/6197 Bladder Increased risk
*the direction of association for the polymorphic allele
Table 5. Observed influence of XRCC3 rs861539 on cancer risk in recent meta-analyses.
Only a few meta-analyses were performed for XRCC3 rs1799794. This polymorphism in 5’UTR
was associated with increased overall and breast cancer risk in earlier studies [64, 82], but the
association with breast cancer was not confirmed [83] and a decreased ovarian cancer risk was
observed in a more recent meta-analysis [12].
4.4. XRCC2
The majority of cancer susceptibility studies focused solely on the XRCC2 rs3218536 SNP.
Different types of cancer were investigated, but most studies were performed in breast and
ovarian cancer. Recent meta-analyses summarized in Table 6 tried to overcome the discrep‐
ancies observed between individual studies [61, 84-86]. All meta-analyses observed an
association of the polymorphic rs3218536 allele with decreased ovarian cancer risk [61, 84,
86]. On the other hand, no association with breast cancer risk was observed in the most recent
meta-analyses [61, 84, 86], confirming the results of a previous meta-analysis [85]. Although
overall cancer risk was also not significantly affected by XRCC2 rs3218536 [86], it was sug‐
gested that different cancer types should be evaluated separately [84]. However, a conclusive
role of XRCC2 rs3218536 in other cancer types is still difficult to ascertain, due to the limited
number of studies investigating a particular cancer. Nevertheless, polymorphic XRCC2
rs3218536 could be associated with increased risk for cancer of upper aerodigestive tract [84].
Apart from separate evaluation of different cancer types, further studies should investigate
the possible interactions that could modify the role of XRCC2 SNPs. Several studies on breast
cancer reported an association only in specific subgroups of patients, suggesting that besides
genetic variability, also environmental factors and gene-environment interactions could
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contribute to cancer risk. Such interactions could also help to explain the effect of low pene‐
trance variants on cancer risk.
Reference N of studies N of cases/controls Cancer type Major observation*
Yu, 2010 [85] 16 18341/19028 Breast No association
He, 2014 [84]
14 17420/17811 Breast No association
6 3035/5554 Ovarian Decreased risk
3 499/583 Upper aerodigestive tract Increased risk
Shi, 2014 [61] 9 3279/5934 Ovarian Decreased risk
Zhang, 2014 [86]
33 26320/28862 Overall No association
12 17230/16485 Breast No association
6 3035/5554 Ovarian Decreased risk
*the direction of association for the polymorphic allele
Table 6. Observed influence of XRCC2 rs3218536 on cancer risk in meta-analyses.
5. Genetic variability in HRR and cancer treatment outcome
Cancer treatment is often associated with severe adverse effects, however there is considerable
interindividual variability regarding the occurrence and severity of adverse effects and
regarding treatment efficacy. As cancer treatment is usually based on the use of chemothera‐
peutic agents and radiation therapy, whose cytotoxic effect results from their ability to induce
DNA damage, pharmacogenetic factors such as polymorphisms in DNA repair pathways can
contribute to observed differences.
Different agents may cause different forms of DNA damage. DSBs can occur due to the
formation of strand crosslinks after treatment with alkylating and platinum-based com‐
pounds. Mechanisms involved in DSB repair may also lead to increased sensitivity to topoi‐
somerase inhibitors such as camptothecines, anthracycline, and etoposide. DSB repair may be
also important for the repair of radiation-induced DNA damage. Genetic variability of HRR
may thus play a role in resistance to chemotherapy, in treatment efficacy and in occurrence of
treatment related toxicities.
There are a lot less pharmacogenetic studies investigating the role of genetic variability in HRR
in cancer treatment outcome compared to studies on cancer susceptibility. In addition, many
studies are small and/or inconclusive and the shortcoming of most of the studies is that DNA
repair capacity itself was not measured. Most pharmacogenetic studies focused on XRCC3
polymorphisms and were predominantly investigating their influence on treatment with
platinum compounds. XRCC3 rs861539 was associated with shorter survival in ovarian and
colorectal cancer [87, 88]. Most studies were however performed in non-small cell lung cancer
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(NSCLC), where XRCC3 rs861539 was associated with better response rate. Even though this
effect was not observed in all the studies, recent meta-analyses confirmed the possible
prognostic value of XRCC3 rs861539 in response to cisplatin-based chemotherapy in NSCLC
patients (Table 7). Although individual studies observed the association of this SNP with
longer overall survival of NSCLC patients [89, 90], that was not confirmed in meta-analyses
[91-93]. Several studies also observed an association of XRCC3 rs861539 with decreased toxicity
of platinum compounds in malignant mesothelioma, colorectal cancer and other malignancies
[94, 95]. XRCC3 rs1799794 was also associated with decreased odds of developing treatment
related toxicities in malignant mesothelioma [95]. Some of the discrepancies observed between
studies could be explained by different chemotherapy regimens used in different cancer types.
Reference N of studies N of cases Major observation*
Shen, 2013 [92] 7 1186 Better response to chemotherapy, no significantinfluence on overall survival
Qiu, 2013 [91] 8 1289 Better response to chemotherapy, no significantinfluence on overall survival
Zhang, 2013 [93] 7 1514 No significant influence on overall survival
*the direction of association for the polymorphic allele
Table 7. Meta-analyses of XRCC3 rs861539 and treatment outcome in non-small cell lung cancer.
The role of genetic variability in other HRR genes in cancer treatment outcome is currently not
well established. Pharmacogenetic studies of other HRR genes were limited to individual
studies in particular cancer types. NBN polymorphisms have been associated with increased
treatment-related toxicity of gemcitabine-platinum combination chemotherapy in patients
with malignant mesothelioma [95]. On the other hand, NBN rs1805794 was associated with
longer progression-free survival in NSCLC patients treated with platinum-based chemother‐
apy, suggesting it might serve as a favourable prognostic factor [96].
RAD51 rs1801320 and rs1801321 polymorphisms were also associated with altered survival in
NSCLC and cervical cancer patients [97-99], but no prognostic role was observed in malignant
mesothelioma or sarcoma patients [95, 100].
Similar to other HRR genes, the potential influence of XRCC2 on cancer treatment outcome
was not studied as often as cancer risk. The low MAF of XRCC2 rs3218536 could be a part of
the reason why there is a lack of studies regarding treatment outcome. XRCC2 rs3218536 was
associated with decreased survival in pancreatic cancer and NSCLC patients [99, 101], but the
association was significant only in specific subgroups of patients. In pancreatic cancer patients,
treated with chemotherapy and radiation, the polymorphic XRCC2 rs3218536 allele was
associated with decreased survival only in patients treated with 5-fluorouracil based chemo‐
radiation, but not in patients treated with gemcitabine based chemoradiation [101]. These
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differences further support observations that the effect of HRR polymorphisms may depend
on the type of DNA damage.
Radiation therapy is used for treatment of up to 50% of cancer patients [102]. Adverse events
are common and affect patients’ quality of life [103]. They occur mainly locally in irradiated
sites and therefore vary between cancer types. Acute toxicities affect rapidly proliferating
tissues, but are usually transient and reversible [102]. Erythema and dermatitis are common
skin acute adverse events, radiation pneumonitis is a typical complication in lung cancer, while
urinary and bowel toxicities occur in prostate cancer.
The new field of radiogenomics aims to identify SNPs associated with radiation toxicity that
could be used for personalized radiation therapy of cancer patients, for example patients with
low risk for adverse events could receive higher doses of radiation [103]. As DSBs represent
the most harmful effect of radiation, several studies have been published regarding HRR SNPs
and radiation toxicity.
NBN polymorphisms did not influence toxicity in prostate, breast or lung cancer [99, 104,
105], but NBN rs1805794 was associated with oral mucositis in head and neck cancer patients
treated with radiation or chemoradiation [106]. RAD51 rs1801320 was also associated with
toxicity in head and neck cancer in one study [107], as well as radiation pneumonitis in lung
cancer patients [99]. Other studies did not report any association of RAD51 SNPs and radiation
toxicity [104, 108-110]. XRCC2 rs3218536 was not associated with radiation toxicity in any of
the studies [99, 104, 111]. Numerous studies investigated the role of XRCC3 poymorphisms in
radiation toxicity, but the results are not conclusive. Several studies found no association [99,
105-107, 109, 111-113], but carriers of polymorphic XRCC3 rs1799794 allele had more toxicity
after radiation treatment of prostate cancer [104, 114] and XRCC3 rs861539 was associated with
increased radiation toxicity in nasopharyngeal cancer [115, 116].
Comparison of radiogenomics studies is difficult, as they were performed in different cancer
types treated with different radiation therapy protocols, sometimes in combination with
chemotherapy. Additionally, different toxicities were selected as endpoints. Nevertheless, the
published data suggest the impact of some of the HRR polymorphisms on the outcomes of
radiation therapy, however meta-analyses are needed to validate these observations.
6. Conclusions
The combined evidence from different studies and meta-analyses suggests that SNPs in HRR
genes contribute to carcinogenesis and could serve as markers of cancer susceptibility. As HRR
proteins often interact in DNA repair, future studies should evaluate if combinations of SNPs
in different HRR genes may serve as a better predictor of susceptibility to various cancers.
Cancer treatments are often characterized by a narrow therapeutic index and a balance
between the desired therapeutic effect and the acceptable treatment-related toxicity has to be
achieved. In the future, the improved understanding of the role of HRR genetic variability in
the response to treatment of a particular cancer with a particular chemotherapeutic regimen
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could contribute to identification of predictive or prognostic biomarkers that could help to
stratify patients based on their risk for adverse events and guide treatment selection. Thus,
treatment from which a particular patient would benefit the most could be selected.
In conclusion, genetic variability in HRR may modify DNA repair capacity and may therefore
play an important role in both cancer susceptibility and the outcome of cancer treatment. A
better understanding of the role of SNPs in HRR genes in different cancers and cancer
treatments is however needed before they could be employed as markers of cancer suscepti‐
bility or treatment outcome in personalized medicine.
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